牛牛AI助手已提取核心信息
EyePoint Pharmaceuticals, Inc. reported its financial outcomes for the fourth quarter and full year ended December 31, 2023, on March 7, 2024. The company announced significant progress in its clinical trials, including positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD, which met all primary and secondary endpoints. The initiation of the first Phase 3 clinical trial for EYP-1901 is expected in the second half of 2024. EyePoint also dosed the first patient in the Phase 2 VERONA trial for diabetic macular edema (DME), with topline data expected in the first quarter of 2025. Additionally, topline data from the Phase 2 PAVIA trial in NPDR is anticipated in the second quarter of 2024. The company appointed Dr. Ramiro Ribeiro as Chief Medical Officer...Show More
EyePoint Pharmaceuticals, Inc. reported its financial outcomes for the fourth quarter and full year ended December 31, 2023, on March 7, 2024. The company announced significant progress in its clinical trials, including positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD, which met all primary and secondary endpoints. The initiation of the first Phase 3 clinical trial for EYP-1901 is expected in the second half of 2024. EyePoint also dosed the first patient in the Phase 2 VERONA trial for diabetic macular edema (DME), with topline data expected in the first quarter of 2025. Additionally, topline data from the Phase 2 PAVIA trial in NPDR is anticipated in the second quarter of 2024. The company appointed Dr. Ramiro Ribeiro as Chief Medical Officer and reported a strong financial position with $331 million in cash and investments as of December 31, 2023. This financial stability is expected to fund operations through the topline data of Phase 3 trials for EYP-1901 for wet AMD in 2026. Total net revenue for the fourth quarter was $14.0 million, a significant increase from the previous year's quarter. The company also completed an upsized underwritten public offering, raising $230 million in December. EyePoint's shares are traded on the Nasdaq Global Market under the symbol EYPT.
EyePoint Pharmicals, Inc.于2024年3月7日公布了截至2023年12月31日的第四季度和全年财务业绩。该公司宣布其临床试验取得重大进展，包括湿性 AMD 中 EYP-1901 的 2 期 DAVIO 2 试验的积极有效性和安全性数据，该试验符合所有主要和次要终点。EYP-1901 的首个 3 期临床试验预计将于 2024 年下半年启动。EyePoint还为VERONA糖尿病黄斑水肿（DME）的2期试验中的第一位患者进行了给药，预计将在2025年第一季度公布顶部数据。此外，NPDR第二阶段PAVIA试验的主要数据预计将在2024年第二季度公布。该公司任命拉米罗·里贝罗博...展开全部
EyePoint Pharmicals, Inc.于2024年3月7日公布了截至2023年12月31日的第四季度和全年财务业绩。该公司宣布其临床试验取得重大进展，包括湿性 AMD 中 EYP-1901 的 2 期 DAVIO 2 试验的积极有效性和安全性数据，该试验符合所有主要和次要终点。EYP-1901 的首个 3 期临床试验预计将于 2024 年下半年启动。EyePoint还为VERONA糖尿病黄斑水肿（DME）的2期试验中的第一位患者进行了给药，预计将在2025年第一季度公布顶部数据。此外，NPDR第二阶段PAVIA试验的主要数据预计将在2024年第二季度公布。该公司任命拉米罗·里贝罗博士为首席医疗官，并报告称，截至2023年12月31日，其财务状况良好，现金和投资为3.31亿美元。这种财务稳定预计将通过 2026 年湿型 AMD EYP-1901 三期试验的主要数据为运营提供资金。第四季度的总净收入为1400万美元，比上一季度大幅增长。该公司还完成了规模扩大的承销公开募股，在12月筹集了2.3亿美元。EyePoint的股票在纳斯达克全球市场上市，股票代码为EYPT。
有用
没用